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Available online 27 July 2016Various types of circulating tumor cell (CTC) detection systems have recently been developed that show a high
CTC detection rate. However, it is a big challenge to ﬁnd a system that can provide better prognostic value
than CellSearch in head-to-head comparison.We have developed a novel semi-automated CTC enumeration sys-
tem (ﬂuidic cell microarray chip system, FCMC) that captures CTC independently of tumor-speciﬁc markers or
physical properties. Here, we compared the CTC detection sensitivity and the prognostic value of FCMC with
CellSearch in breast cancer patients. FCMC was validated in preclinical studies using spike-in samples and in
blood samples from 20 healthy donors and 22 breast cancer patients in this study. Using spike-in samples, a sta-
tistically higher detection rate (p=0.010) of MDA-MB-231 cells and an equivalent detection rate (p=0.497) of
MCF-7 cells were obtained with FCMC in comparison with CellSearch. The number of CTC detected in samples
from patients that was above a threshold value as determined from healthy donorswas evaluated. The CTC num-
ber detected using FCMCwas signiﬁcantly higher than that using CellSearch (p=0.00037). CTC numbers obtain-
ed using either FCMC or CellSearch had prognostic value, as assessed by progression free survival. The hazard
ratio between CTC+ and CTC− was 4.229 in CellSearch (95% CI, 1.31 to 13.66; p = 0.01591); in contrast, it
was 11.31 in FCMC (95% CI, 2.245 to 57.0; p = 0.000244). CTC detected using FCMC, like the CTC detected
using CellSearch, have the potential to be a strong prognostic factor for cancer patients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Breast cancer1. Introduction
Circulating tumor cells (CTC) are cancer cells that are present in the
blood stream among 5 × 106/mL of leukocytes and 5 × 109/mL of red
blood cells (Allard et al., 2004). CTC are considered to be an important
clue for estimation of the possibility of metastasis formation (Fidler,ic cell microarray chip; CM, cell
TokyoMetropolitan Cancer and
okeratin; PFS, progression free
PD, disease progression; CT,
radient centrifugation; EMT,
. This is an open access article under2003) and are expected to be a prognostic marker of cancer patients
(Cristofanilli et al., 2005). Therefore numerous technologies for analysis
of CTC have been developed in the past decade (Joosse et al., 2014;
Haber and Velculescu, 2014; Ignatiadis et al., 2015; Ferreira et al.,
2016). One such technology, the CellSearch system, has been used in a
number of prospective clinical trials and is the only CTC detection sys-
tem approved by the FDA. These clinical trials indicated that the number
of CTCs detected using CellSearch had prognostic value in patients with
breast, colon, prostate, non-small cell lung, small cell lung and gastric
cancer (Cristofanilli et al., 2004; Cohen et al., 2008; de Bono et al.,
2008; Krebs et al., 2011;Naito et al., 2012;Matsusaka et al., 2010). In pa-
tients with breast cancer in particular, CellSearch detection of just one
CTC in the early stage had prognostic value (Lucci et al., 2012). Thus,
CellSearch is thought of as a ﬁrmly established system that can indicate
strong prognostic value in breast cancer.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CellSearch system, can potentially lose CTCs,whichmight affect the sen-
sitivity of CTC detection. Because of the low abundance of CTC in blood,
almost all methods of CTC detection require enrichment of CTC from
blood cells using label-dependent or physical property-based selection
(Joosse et al., 2014). These enrichment processes may possibly reduce
CTC detection sensitivity. Therefore, an enrichment process with mini-
mal CTC loss that is independent of protein expression or a physical
property is needed.
To overcome such problems, we previously developed the cell mi-
croarray chip (CM chip) that enables high sensitivity detection of rare
cells in blood such as malaria-infected erythrocytes or spiked-in cancer
cells (Yatsushiro et al., 2010; Yamamura et al., 2012). The CM chip en-
ables rare cell detection independent of cell surface protein expression
with few enrichment steps. In order to increase the detection sensitivity
and robustness of the CM chip, we developed a ﬂuidic cell microarray
chip (FCMC) device and a semi-automated FCMC system based on the
CM chip, which aimed to eliminate the possibilities of target cell loss.
In this article, we show the performance of this FCMC system in pre-
clinical studies and the results of head-to-head comparisons of the CTC
detection rate of the FCMC systemwith that of the CellSearch system in
patients with breast cancer. Importantly, we also compare the prognos-
tic impact of the FCMC systemwith the CellSearch system in this study.
2. Materials and Methods
2.1. Study Participants
All patients and healthy donors in the present studies below provid-
ed informed consent and their participation in the studieswas approved
by the institutional review committee of Konica Minolta, Inc., the Na-
tional Cancer Center Hospital (NCCH; Tokyo, Japan) and the TokyoMet-
ropolitan Cancer and Infectious Diseases Center Komagome Hospital
(CICK; Tokyo, Japan). Patients who were pathologically diagnosed
with breast cancer, and healthydonorswhodid not have any cancer his-
tory were recruited. Patients who had double cancers or who had any
prior cancer history were not eligible for the present studies. This
work was carried out in accordance with the Code of Ethics of the
World Medical Association (Declaration of Helsinki).
2.2. Fluidic Cell-Microarray-Chip Device (FCMC Device)
We developed the FCMC device based on the CM chip as shown in
Fig. 1-A. About 18,000microchamberswere contained in the redesigned
CM chip; eachmicrochamber was 120 μm in diameter at the top, 90 μm
in diameter at the bottom, and 50 μmdeep (Fig. 1-B). The proximal and
distal distance of microchambers from each other was 200 μm and
300 μm, respectively (Fig. 1-C). We coated BSA on the chip surface on
the outside of themicrochambers after UV-ozone exposure. A BSA coat-
ing prevents nonspeciﬁc adsorption of cells onto the surface. This coat-
ing supported the movement of untrapped cells into the
microchambers. We formed a ﬂow channel by bonding a cover plate
to the new CM chip using black double-sided adhesion ﬁlm. The bond-
ing process formed a ﬂow channel (15 mm wide, 50 mm long and
100 μm deep (Fig. 1-B, D). Each microchamber can hold approximately
50 cells inside as a tight monolayer in a state in which the ﬂuorescent
intensity of every cell can be easily analyzed (Fig. 1-E, F). Therefore,
one FCMC device can analyze up to 9 × 105 cells. The use of multiple
FCMC devices enabled CTC enumeration in this study.
2.3. Blood Processing for the FCMC System
Peripheral blood samples (2 mL, anticoagulated with EDTA) for CTC
analysis were collected after withdrawal of the ﬁrst several milliliters of
blood for clinical use to avoid potential skin cell contamination from the
venipuncture. Two milliliters of blood sample were processed usingFicoll-Paque PLUS (GE Healthcare, Little Chalfont, UK). Precipitated
cells were ﬁxed with 4% formaldehyde, and were then suspended into
340 μL PBS (Supplementary Fig. S1). Theworkﬂowof sample processing
is shown in Fig. 2-A. Based on preliminary experiments (Supplementary
Fig. S2), the samples were processedwithin three hours after blood col-
lection, and were then analyzed with the FCMC device within three
days.
2.4. Formation of Cell Monolayers in Microchambers Using the FCMC
Device
The FCMC device was ﬁlled with PBS before loading the cell suspen-
sion. Cells were trapped in the microchambers as a monolayer by the
following steps (Fig. 2-B and Supplementary Fig. S3). One ﬁfth of the
cell suspension (68 μL) was loaded from the reservoir tank into the
ﬂow channel by suction. The cells had completely settled down on the
chip surface within 1 min. At this time, many excess cells remained on
the chip surface. We subsequently applied two automated suction
methods to improve cell capture efﬁciency, termed “Suction for Trap-
ping” and “Suction for Monolayer”. “Suction for Trapping” involves
10 cycles of a brief suction (suction rate, 0.1 mL/min; total volume of
suction, 0.3 μL) and incubation (10 s). This step moves untrapped cells
gradually towards downstream microchambers. “Suction for Monolay-
er” is a long suction (suction rate, 0.1 mL/min; total volume of suction,
41 μL) followed by an incubation (10 s). This step moves overlapped
cells out of microchambers. Cells that are present as monolayers at the
bottom of the microchambers can maintain their position during the
time of “Suction for Monolayer” because the height of the cell monolay-
er at the bottom of the microchamber (10 μm) means that these cells
are little affected by suction ﬂow as the in-silico simulation shows
(Fig. 3-A). After ten repetitions of “Suction for Trapping” and “Suction
for Monolayer”, all cells are completely trapped as a monolayer (Fig.
3-B, C).
2.5. Immunostaining for Discriminating CTCs From Leukocytes
The ﬁrst immunostaining solution, which included 1:2 diluted anti-
cytokeratin (CK) mAb CAM5.2 (Becton, Dickinson and Company, San
Jose, CA) and 1:50 diluted anti-human CD45 mAb HI30 (BioLegend,
San Diego, CA) in PBS solution containing 1% Tween 20 (Calbiochem,
San Diego, CA) and 3% BSA (Thermo Fisher Scientiﬁc, Lafayette, CO),
was loaded onto the FCMC device. After incubation for 30 min at room
temperature and washing with PBS, the second immunostaining solu-
tion was then loaded. The second immunostaining solution included
1:500 diluted Alexa Fluor 488Goat Anti-Mouse IgG1 (γ1) (Life Technol-
ogies, Grand Island, NY), 1:500 dilutedAlexa Fluor 647Goat Anti-Mouse
IgG2a (γ2a) (Life technologies) and 1:1000 diluted Hoechst 33342
10 mg/mL solution (Life technologies) in PBS solution containing 1%
Tween 20 and 3% BSA. After incubation for 30min at room temperature,
unbound mAbs were washed out with PBS.
2.6. Detection of CTCs in Fluorescent Microscopic Images
Immunoﬂuorescent stained cells in the FCMC systemwere analyzed
using an Axio Imager M2 ﬂuorescence microscope equipped with stan-
dard ﬁlter sets (49, 38HE, 50 for Hoechst 33342, Alexa488, and Alexa
647 respectively), a monochrome CCD camera, (AxioCam MRm), a 5×
objective (EC Plan-NEO FLUAR) and ZEN2012 blue edition software
(Carl Zeiss, Jena, Germany). Approximately 400 views were captured
to cover the entire area of the microchamber. The ﬂuorescence images
were analyzed using in-house software that identiﬁes candidate CTCs.
First, the software identiﬁed cells that were CK+ and Hoechst 33342+.
If these cells displayed a strong CD45 signal, the software excluded
them as CTC candidates. Next, multiple skilled inspectors examined
the list of candidates and manually excluded CD45weak cells from the
list of CTC candidates. Each candidate was shown with its
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Fig. 1.A schematic outline of CTC detection using the FCMC system. (A) Assembled FCMC device (top side) and cross-sectional scanning electronmicroscope image of themicrochambers
(bottom side). The rectangular area indicates the area used for ﬂatnessmeasurement, the arrow indicates the area used formeasurement of roughness and the circle enclosing awhite line
indicates the area used for measurement of the radius of the microchamber rim. (B) A zoomed side view of the ﬂow channel over the microchamber. The depth, and the top and bottom
diameter of eachmicrochamber, and the height of theﬂow channel are indicated. (C) A zoomed top viewof the ﬂow channel. Distances betweenmicrochambers are indicated. The orange
colored area is coatedwith BSA. (D) A top view of the ﬂow channel. The size of the ﬂow channels and the microchamber area are indicated. (E) Bright ﬁeld view of cells trapped as a tight
monolayer in a microchamber. (F) Immunostained cells inmicrochambers. All of the cells are trapped inmicrochambers. Leukocytes are immunostained with an anti-CD45 antibody and
labeled with Alexa ﬂuor 488 dye (green). Blue: Hoechst 33342 (nucleus).
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ground noise. Bright-ﬁeld images were also examined for morphologi-
cal discrimination of non-cell materials.
2.7. Cell Lines
The breast cancer cell lines, MDA-MB-231 and MCF-7, were used for
preclinical spike-in experiments. MDA-MB-231 andMCF-7were obtained
from the ATCC (Manassas, VA) and the JCRB Cell Bank (Osaka, Japan), re-
spectively. All cell lines were authenticated by DNA STR proﬁling. MDA-
MB-231 cells weremaintained in Leibovitz's L-15medium (Life technolo-
gies), and the MCF-7 cell line was maintained in MEM Earle's medium
(Life technologies) containing 10% fetal bovine serum (GE Healthcare),
penicillin, streptomycin and amphotericin B (10,000 U/mL, 10 mg/mL
and 25 μg/mL, respectively; Sigma-Aldrich, St. Louis, MO) under a humid-
iﬁed atmosphere containing 5% CO2 at 37 °C.
2.8. Evaluation of the Capture Efﬁciency of the FCMC SystemWithout Blood
Processing
MDA-MB-231 cells, and leukocytes isolated from healthy donor's
blood by using Ficoll-Paque PLUS separation medium, were used. Each
cell type was ﬁxed with 4% formaldehyde and washed with PBS.
MDA-MB231 cells (1 × 103 cells) were spiked into 5 × 105 leukocytes
in 68 μL of PBS. MDA-MB231 cells were detected in the cell suspension
by the FCMC system without blood processing. Cell capture efﬁciency
was calculated using the detected MDA-MB231 counts divided by the
spiked MDA-MB231 counts.2.9. Evaluation of the FCMC System Using Spiked-in Blood
MDA-MB-231 or MCF-7 cells were spiked into 2 mL of blood for the
FCMC systemor into 10mL of blood for the CellSearch system. The spiked
cell counts were determined using a serial dilution method. Two millili-
ters of spiked-in blood was processed using Ficoll-Paque PLUS and two
ﬁfths of the volume of the blood were analyzed using two FCMC devices.
Ultimately, the detected cell counts per 0.8 mL of blood were obtained
(Supplementary Fig. S1). To evaluate linearity of cell recovery, we used
16, 63, 250 or 500 ofMDA-MB-231 cell-spiked blood. The slope and coef-
ﬁcient of determination (R2) were calculated by regression analysis. The
percentage recovery of each cell line was calculated using “the detected
cell line counts” divided by two ﬁfth of “the spiked cell line counts”. The
difference in the percentage cell recovery between the FCMC system
and the CellSearch system was evaluated using t-test statistical analysis.2.10. Evaluation of the FCMC System Using Samples From Healthy Donors
and Breast Cancer Patients
We analyzed samples from twenty healthy donors and twenty two
breast cancer patients using the FCMC system. The healthy donors
were recruited in Konica Minolta, Inc. and the patients were recruited
in NCCH and CICK. Two milliliters of blood was processed by Ficoll-
Paque PLUS and four ﬁfths of the volume of the blood were analyzed
by using four FCMC devices. Ultimately, CTC counts per 1.6 mL of blood
were obtained (Supplementary Fig. S1). The ﬁrst ﬁve patients in NCCH
were analyzed using an FCMC device that has approximately 15,000
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Fig. 2.Workﬂowof sample processing andmovement of cells in the FCMC device. (A)Workﬂowof sample processing and CTC detection. (a) Blood sample collection and enrichment using
Ficoll-Paque PLUS. (b) The cell suspension is loaded into the FCMC device. The cells form monolayers in the microchambers and are immunostained by using a syringe pump. (c) All
microchambers are scanned using a ﬂuorescent microscope. (d) CTC are detected from the ﬂuorescent images. (B) Movement of cells in the FCMC device. (a) The new CM chip, which
is made from polystyrene (PS), is cleaned with UV ozone and coated with BSA. (b) The FCMC device is washed with PBS. (c) A cell suspension (68 uL) that is equivalent to 0.4 mL of
blood is loaded into one FCMC device. (d) After “Suction for Trapping”, untrapped cells move into downstream microchambers and settle down on the bottom of these
microchambers. The blue arrows indicate ﬂow. (e) After “Suction for Monolayer”, overlapped cells are discharged from microchambers and move to the outside of microchambers or
to the inside of downstream microchambers. (f) After repetitions of (d) and (e), all cells are trapped in a monolayer. (g), (h), (i) Immunostaining solutions are loaded, incubated and
washed.
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were also analyzed using the CellSearch system. We compared CTC
counts per 7.5mL blood of breast cancer patients between the FCMC sys-
tem and the CellSearch system usingWilcoxon's signed rank test.
2.11. Statistical Analysis Software
EZR (Saitama Medical Center, Jichi Medical University), which is a
graphical user interface for R (The R Foundation for Statistical Comput-
ing, version 2.13.0), was used for statistical analyses (Kanda, 2013).
3. Results
3.1. Complete Cell Capture From Cultured Cell Suspensions Using the FCMC
Device
We developed the FCMC device by mounting a micro ﬂuid channel
onto the redesigned CM chip of the previous CM system. An overview
of the redesigned system with the micro ﬂuid channel, and its use for
CTC detection, is shown in Figs. 1 and 2-A. The new chip has a smooth
surface, a ﬂatness area and a sharp edge. The surface roughness (Ra)
of the bottom of the microchamber is 9–10 nm (Fig. 1-A, white
arrow). The ﬂatness of the microchamber area is 21–25 μm (Fig. 1-A,
white rectangle). The edge (R) of the microchamber is lower than
0.005 (Fig. 1-A, white circle). We evaluated the cell-trapping efﬁciency
of the FCMC device using an automated suction algorithm. The suctionalgorithm is shown in Supplementary Fig. S3. After initial loading of
6 × 105 leukocytes, only 54% of the leukocytes were trapped in the
micro chambers. Untrapped cells were subsequently trapped in the
microchambers by repetition of the brief suction and the incubation.
Complete cell capture was achieved after a total of ten brief suctions
and incubations (Fig. 3-B, C). Cell capture in a monolayer in the
microchambers was promoted by the ﬂow in the microﬂuid channel
and by the hydrodynamic design of the ﬂow channel (Fig. 3-A, D). We
then evaluated the capture efﬁciency of 1 × 103 MDA-MB-231 cells
mixedwith 3× 105 leukocytes using the FCMCdevice. After cell capture,
we detected MDA-MB 231 by immunoﬂuorescent staining. The per-
centage detection of the MDA-MB-231 cells was 100 ± 10% (mean ±
SD). The accuracy of the cell counting chamber used for MDA-MB-231
cell preparation includes 10% of SD. Therefore, the FCMC device had
extra-high potential for CTC detection after removal of red blood cells
from the blood samples.
3.2. Linearity of the FCMC System Using Spiked-in Blood
The detection efﬁciency of rare cells in blood using the FCMC system
was evaluated using serial dilutions of MDA-MB231 cells spiked into
2 mL of blood from healthy donors. The expected number of spiked-in
cells, plotted against the actual number of cells observed in the samples,
is shown in Fig. 4-A. Regression analysis of the number of observed
tumor cells versus the number of expected tumor cells produced a
slope of 0.71, and a coefﬁcient of determination (R2) of 0.94. The
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centage cell recovery was: 82% ± 42%, 78% ± 26%, 81% ± 19% and
75% ± 14% of 6, 26, 100 and 200 spiked cells, respectively.
3.3. Comparison of the Recovery Rate of Cancer Cells Between the FCMC and
the CellSearch System
The spiked cancer cell recovery rate of the FCMC system was com-
pared with that of the CellSearch system using MCF-7 and MDA-MB-
231 cell spiked-in blood samples. MCF-7 cells express CK and EpCAM
but have low Vimentin expression. MDA-MB-231 cells are CKweak,
have low EpCAM expression, and express Vimentin (Supplementary
Fig. S4). Each cell line was spiked into blood from a healthy donor sothat the spiked bloodwas at a concentration of 32 cells per mL. The per-
centage cell recovery of the two cell lines is shown in Fig. 4-B. Using the
FCMC system, the percentage recovery of MDA-MB-231 cells was
66% ± 14%, and that of MCF-7 cells was 73% ± 34%. On the other
hand, using the CellSearch system, the percentage recovery of MDA-
MB-231 cells was 12% ± 15%, and that of MCF-7 cells was 89% ± 13%.
No statistical difference was found between the percentage recovery
ofMCF-7 cells using the FCMC system and that using the CellSearch sys-
tem (p = 0.497, t-test). In contrast, the percentage recovery of MDA-
MB-231 cells obtained using the FCMC system was signiﬁcantly higher
as compared to that obtained using the CellSearch system (p= 0.010,
t-test). Typical immunoﬂuorescence images of MDA-MB-231 and
MCF-7 cells detected using the FCMC system are shown in Fig. 4-C.
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Table 1
CTC counts in healthy donors detected using the FCMC system. The CTC counts in 1.6 mL
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We also analyzed the CTC count per 1.6 mL of peripheral blood from
each of 20 healthy donors in Konica Minolta, Inc. (Tokyo, Japan) using
the FCMC system, in order to determine a threshold value for the CTC
counts using this system. The number of cells analyzed from 1.6 mL of
peripheral blood after enrichment is about 1.6 × 106. The mean ± SD
value of these CTC countswas 0.6±0.8, and 90% (18/20) of the samples
had CTC counts ≤1 (Table 1). No sample had a CTC count ≥4.blood of 20 healthy donors were analyzed using the FCMC system.
CTC counts/1.6 mL
blood
Number of healthy donors
(N= 20)
0 11 (55%)
1 7 (35%)
2 1 (5%)
3 1 (5%)3.5. CTC Counts in Samples From Patients With Advanced Breast Cancer
We then compared the CTC counts detected in samples of patients
with advanced breast cancer using the FCMC systemwith those detect-
ed using the CellSearch system (Table 2). Samples from 17 advancedbreast cancer patients from CICK and from 5 advanced breast cancer pa-
tients from NCCH were evaluated. All patients were under treatment at
the time of blood collection, and then the type of treatment and their re-
sponses are noted in Table 2. In total, CTCs were detected in 17/22
(77.3%) of these samples; the FCMC system detected CTCs in all 17 sam-
ples whereas, in contrast, the CellSearch system detected CTCs in only 8
Table 2
Patient characteristics and the results of CTC counts. The CTC counts of 22 patients with breast cancer were analyzed using the FCMC system or the CellSearch system. *, the CTC counts of
patients numbered 1–5were analyzed using an FCMC device that had about 15,000microchambers in theﬂowchannel, and the counts of patients numbered 6–22were analyzed using an
FCMC device that had about 18,000microchambers. **, CTC counts detected in 1.6mL blood using the FCMC system are normalized to a value of 7.5 mL. All patients were under treatment
of chemotherapy or hormonotherapy. The results of the most recent CT evaluation for disease are listed. Abbreviations: female, F. CT, chemotherapy. HT, hormonotherapy. PR, partial re-
sponse. SD, stable disease. PD, progressive disease.
Patient * Age/sex Metastatic site Treatment type
Current response
to therapy
CTC count (FCMC system)
/7.5 mL**
CTC count (CellSearch system)
/7.5 mL
1 58/F Lung, bone, liver, adrenal gland, brain CT SD 4.7 0
2 64/F Bone, liver CT SD 160 4
3 42/F Lung, lymph node, brain CT PD 52 3
4 63/F Bone, lymph node, liver, pleura CT PD 110 64
5 41/F Lung, bone, liver CT SD 0 0
6 67/F Bone, liver, lymph node CT SD 0 0
7 47/F Bone, lymph node, brain CT SD 160 1
8 54/F Lung, bone, lymph node, adrenal gland, peritoneum CT PR 4.7 0
9 67/F Liver HT SD 9.4 0
10 68/F Breast, lung, bone CT SD 12,400 88
11 52/F Breast, lung, bone, skin, lymph node, pleura, brain CT PD 19 0
12 56/F Bone, lymph node, adrenal gland CT SD 9.4 2
13 53/F Pleura, brain CT SD 4.7 0
14 54/F Bone CT SD 0 0
15 82/F Pleura, bone HT SD 4.7 0
16 67/F Bone, pleura HT SD 0 0
17 82/F Lung, bone, liver, lymph node HT SD 9.4 13
18 47/F Bone CT SD 0 0
19 72/F Bone HT SD 9.4 0
20 77/F Lymph node CT SD 33 0
21 62/F Lung, bone, liver, lymph node, adrenal gland HT SD 230 31
22 41/F Lung, bone, lymph node HT SD 4.7 0
179T. Sawada et al. / EBioMedicine 11 (2016) 173–182out of these 17 samples. Although the FCMC system detected fewer
CTCs than the CellSearch system in one sample (patient number 17),
when all of the sampleswere analyzed the FCMC systemdetected statis-
tically higher counts of CTCs than those detected by the CellSearch sys-
tem (p b 0.00037, Wilcoxon signed rank test) (Fig. 5-A). There was a
good correlation between the counts of CTCs detected with both
methods (0.764; Spearman rank-correlation coefﬁcient). Typical immu-
noﬂuorescent images of a CTC from a patient with breast cancer are
shown in Fig. 5-B.
3.6. CTC Counts and Progression Free Survival
We analyzed the association between CTC counts and progression
free survival (PFS). PFSwas deﬁned as the time betweenblood sampling
for CTC analysis and disease progression (PD). The result of 20 healthy
donor samples was used to determine the threshold level of the FCMC
system as 3 CTCs/1.6 mL. After a median follow-up period of 206 days,
the median PFS was signiﬁcantly shorter in the patients in whom the
number of CTC detected using the FCMC system was above the thresh-
old level (CTC+) (40 days; 95% CI, 0 days to N.E., not estimable) than in
the patients in whom the number of detected CTC was not above the
threshold level (CTC−) (194 days; 95% CI, 173 days to N.E.; p =
0.000244; HR, 11.31; 95% CI, 2.245 to 57.0; p = 0.003284) (Fig. 5-C).
Similarly, using CellSearch, the median PFS was shorter in the patients
in whom the number of detected CTC was above the threshold level of
1/7.5 mL that was determined in a previous study (Allard et al., 2004)
(CTC+) (97 days; 95% CI, 0 days to 173 days) than in the patients in
whom the number of detected CTC was not above the threshold level
(CTC−) (325 days; 95% CI, 33 days to N.E.; p = 0.0082; HR, 4.229;
95% CI, 1.31 to 13.66; p = 0.01591) (Fig. 5-D). Three patients had
been evaluated by CT scanning and had been conﬁrmed as PD at the
same time as their blood collection.
4. Discussion
The CellSearch system precedes other methods for CTC detection.
Since CellSearch was described various other types of CTC detectionsystems have been developed and their advantages and disadvantages
have been reviewed (Joosse et al., 2014; Haber and Velculescu, 2014;
Ignatiadis et al., 2015; Ferreira et al., 2016). Those CTC detection systems
are categorized according to the method of CTC enrichment and/or de-
tection. For example, they are based on immunoafﬁnity (positive selec-
tion (Nagrath et al., 2007; Talasaz et al., 2009; Stott et al., 2010;
Saucedo-Zeni et al., 2012), negative selection (Liu et al., 2011; Sawada
et al., 2016)), biophysical properties (density gradient centrifugation
(Campton et al., 2015; Morimoto et al., 2015), microﬁltration (Vona et
al., 2000; Adams et al., 2014; Sarioglu et al., 2015), inertial force
(Ozkumur et al., 2013; Sollier et al., 2014), electrophoresis (Gupta et
al., 2012; Peeters et al., 2013), acoustophoresis (Augustsson et al.,
2012)), direct imaging (Galanzha and Zharov, 2012; Marrinucci et al.,
2012) and functional characteristics (Lu et al., 2010; Alix-Panabieres,
2012). Although the CTC detection rate of some of these methods ex-
ceeds that of the CellSearch system, to ﬁnd a method that shows better
clinical signiﬁcance for the number of detected CTCs compared to
CellSearch is considered to be a big challenge. In this study, we showed
the high capture efﬁciency of the FCMC device using cell suspensions,
and a good linearity of cell recovery rate using cancer cells spiked into
blood. We obtained a higher rate of CTC detection in samples from ad-
vanced breast cancer patients using the FCMC system than that using
the CellSearch system. Furthermore, we found that the number of CTC
detected using the FCMC system provided a better prognostic value
than the number detected using the CellSearch system.
We have previously reported the CM chip that enables precise esti-
mation of rare cell counts in blood including spiked-in cultured cancer
cells (Yatsushiro et al., 2010; Yamamura et al., 2012). Although the
CM chip produced excellent results in a preclinical study, we considered
that precise enumeration of CTCs requires analysis of all cells, including
the excess cells that might be excluded from the chambers. Thus it was
considered that washing of the chip surface might result in the loss of
such cells, and may lead to an underestimation of the CTCs present in
the sample. Excess cells were classiﬁed as “untrapped cells” and “over-
lapped cells” (Fig. 2-B). Untrapped cells are cells that remain outside
of the microchambers. Overlapped cells are cells that are inside of the
microchambers but have not adhered to the bottom of the
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Fig. 5. Comparison of the CTC counts detected in patientswith breast cancer using the FCMC systemand the CellSearch system, andprogression free survival in patients inwhomCTCwere
detected or not detected using the FCMC system or the CellSearch system. (A) The CTC counts of twenty-two patients with breast cancer were evaluated. For comparison with the
CellSearch system, the results of the FCMC system from 1.6 mL blood were normalized to a value of 7.5 mL. The number of CTC counts detected using the FCMC system was
statistically higher than that using the CellSearch system (p = 0.00037, Wilcoxon signed rank test). (B) Typical immunoﬂuorescence stained CTC images of a patient with breast
cancer. CTC was deﬁned as cytokeratin (CK) positive, CD45 negative and Hoechst 33342 (nucleus) positive. Scale bar, 20 μm. (C,D) Kaplan-Meier curves of progression free survival
(PFS) in patients in whom CTC were detected (CTC+) or not detected (CTC−) using (C) the FCMC system or (D) the CellSearch system are shown. CTC+ is deﬁned as detected CTC
counts that are above the threshold level of each system (FCMC, 3 CTC/1.6 mL; CellSearch, 1 CTC/7.5 mL). The log-rank test of PFS showed signiﬁcant differences according to CTC
detection in both systems (FCMC: p= 0.000244, CellSearch: p= 0.0082). The median PFS of CTC+ patients (40 days; 95% CI, 0 to N.E., not estimable) and CTC− patients (194 days;
95% CI, 173 to N.E.) as assessed using the FCMC system is shown in (C). The median PFS of CTC+ patients (97 days; 95% CI, 0 to 173) and CTC− patients (325 days; 95% CI, 33 to N.E.)
as assessed using the CellSearch system is shown in (D). The hazard ratio for PFS was 11.31 (95% conﬁdence interval [CI], 2.245 to 57.0; p= 0.003284) for CTC+ patients as compared
with CTC− patients using the FCMC system, and was 4.229 (95% CI, 1.31 to 13.66; p = 0.01591) for CTC+ patients as compared with CTC− patients using the CellSearch system.
Patients remained in the study unless they met a criterion for disease progression.
180 T. Sawada et al. / EBioMedicine 11 (2016) 173–182microchamber as a cell monolayer. In order to trap all of the cells as a
monolayer in the microchambers, we improved the CM chip and
adopted an automated suction algorithm (Supplementary Fig. S3)
which enables efﬁcient cell trapping as a monolayer. We arranged the
positions of the microchambers between the inlet and the outlet in
order to trap cells efﬁciently during suction (Fig. 3-D). In an in silico
ﬂow simulation, the FCMC device has a low-speed area in a
microchamber at a height of 10 μm from the bottom, and this helps to
retain cells as a monolayer (Fig. 3-A). Cells can be trapped as amonolayer in all of the microchambers only by use of the FCMC device
with this automated suction algorithm.
In this study, the FCMC system showed higher sensitivity in detec-
tion of CTCs in patients with advanced breast cancer than CellSearch.
A previous report showed the presence of CTC that were CK+ and
EpCAM− in the blood that was discarded by CellSearch after EpCAM-
based enrichment (Wit et al., 2015). The FCMC system has the advan-
tage that it enriches CTC independent of CTC EpCAM expression,
which enables detection of such CK+ and EpCAM− CTC. Additionally,
181T. Sawada et al. / EBioMedicine 11 (2016) 173–182the FCMC system adopts only a density gradient centrifugation (DGC)-
based enrichment step. DGC-based CTC enrichment is often combined
with another enrichment procedure such as depletion of CD45+ cells
because it is difﬁcult to detect CTC in the presence of too many residual
leukocytes (Lustberg et al., 2012). Although the loss of cells is kept to a
minimum in DGC-based enrichment, additional enrichment steps may
induce unexpected target cell loss. In the FCMC system, one FCMC de-
vice can completely capture about 9 × 105 cells. Generally, the mean re-
covery numbers of cells by the DGC-based enrichment step is
1.0 × 106 cells/mL of blood (Nilsson et al., 2008); therefore, several
FCMC devices are sufﬁcient for enumeration of CTC in that situation.
This efﬁciency may contribute to the high sensitivity in CTC detection
of the FCMC system. However, the CTC positive detection rate is still
low at 36.4% (8/22), even in the FCMC system. The probable reason is
that all patients in this studywere under treatment, whichmight be ex-
pected to result in low CTC counts as suggested in previous reports
(Riethdorf et al., 2010; Pierga et al., 2008). In order to increase the CTC
detection rate, it might be helpful to use arterial blood instead of periph-
eral blood (Terai et al., 2015).
In spike-in experiments, the FCMC system could detect EpCAM−,
CKweak and Vimentin+ MDA-MB-231 cells (Fig. 4-C, Supplementary
Fig. S4). The presence of CTCs that express mesenchymal components
such as vimentin, the so called Epithelial Mesenchymal-Transition
(EMT)-CTC,waspreviously reported in advanced breast cancer patients,
and the expression level of such components changes dramatically in
disease progression (Yu et al., 2013). Moreover, recent reports have
shown that the heterogeneity of CTC reﬂects various degrees of epithe-
lial and mesenchymal cell-surface expression depending on the EMT
status of the CTC (Polioudaki et al., 2015; Satelli et al., 2015). Indeed,
variation in the level of CK expressionwas observed in the CTC detected
in this study (Supplementary Fig. S5). Although proof of the expression
ofmesenchymal components in CTC is lacking in this study, detection of
those cells using the FCMC system may also contribute to the high sen-
sitivity in CTC detection of this system. The FCMC system includes pre-
cise location information regarding the chamber that includes the
target cell. It therefore enables recovery of target cells for further analy-
sis. Futuremolecular characterization of those CTCsmay reveal the rela-
tionship between disease progression and various types of CTCs.
Regarding the prognostic value of CTC, detection of CTCs over the
threshold value (CTC+ patients) in both the FCMC and CellSearch sys-
tem was a worse prognostic factor in this study. The signiﬁcant point
that needs to be noted here is that the hazard ratio between CTC+
and CTC− patients using the FCMC system was much greater than
that between CTC+ and CTC− patients using CellSearch. This result in-
dicated that, like the CTC detected using CellSearch, the number of CTC
detected using the FCMC system also has the potential to be a strong
prognostic marker for cancer patients. An important question is why
the FCMC system results have a better prognostic value than the
CellSearch results in this study. One possible reason is that the FCMC
system detected EMT-CTC. It has been suggested that the presence of
EMT-CTC may be associated with an unfavorable outcome (Joosse et
al., 2012). EMT is assumed to be an essential state for metastasis
(Gunasinghe et al., 2012), and therefore a relationship between the de-
tection of EMT-CTC and short time to disease progression is reasonable.
On the other hand, in contradiction to our result, a previous report
showed that the presence of EpCAM− and CK+ CTC was related to a fa-
vorable outcome (Wit et al., 2015). Additionally, we could not ﬁnd a re-
lationship between the number of metastatic sites and the CTC counts
using the FCMC system. Both our study and the previous study analyzed
a small number of patients, which makes it difﬁcult to come to any de-
ﬁnitive conclusion.
Recently, the presence of the aggregates containing two or more
CTCs (CTC clusters) has also been associated with poor prognosis in pa-
tients with metastatic cancer (Aceto et al., 2014). In addition, CTC clus-
ters are considered as biomarkers for early detection of cancer (Carlsson
et al., 2014) and as a potential tool for themonitoring of tumor-immunecell interactions (Sarioglu et al., 2015). The FCMC system is capable of
detecting CTC clusters in a spike-in experiment usingMCF-7 cells (Sup-
plementary Fig. S6), however, we did not detect any CTC clusters in this
patient study. We consider that the limited number of patients and
healthy volunteers is a limitation of this study. We also consider that
the use of PFS as an indicator for evaluating and estimating the clinical
signiﬁcance of CTC counts is not sufﬁcient. In order to conﬁrm the ﬁnd-
ings in this study, a larger study is required with evaluation of overall
survival of the patients.
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